Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025-03 · 23 (3) · 341-354
DOI: 10.1111/ddg.15639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 26.12.2024. Verfasst von Chalid Assaf und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Helios Klinikum Krefeld, Krefeld, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Skin Neoplasms, Mycosis Fungoides, Sezary Syndrome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T‐cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C‐C chemokine receptor 4 (CCR4)‐directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second‐line treatment of stage IB and above SS and MF, after at least one prior systemic therapy. Since then, new insights on safety and efficacy of mogamulizumab were generated by post hoc analyses and real‐world evidence. A panel of CTCL‐experts discussed available literature and own experiences and developed relevant recommendations on the use of mogamulizumab in clinical practice in Germany. The recommendations cover patient criteria, prior therapies, use of mogamulizumab as monotherapy or combination therapy, management of side effects, duration of therapy, and monitoring schedules. The aim of these clinical recommendations is to support healthcare professionals in their decision‐making and use of mogamulizumab in daily practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Helios Klinikum Krefeld, Krefeld, Germany.
- Institute for Molecular Medicine, MSH Medical School Hamburg, Hamburg, Germany.
- Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Dermatology and Venereology, Klinikum Ludwigshafen, Ludwigshafen, Germany.
- Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Radiation Oncology, Münster University Hospital, Münster, Germany.
ORCID-Profile: Chalid Assaf, Edgar Dippel, Gabor Dobos, Rudolf Stadler
Zitieren
APA
Assaf, C., Booken, N., Dippel, E., Dobos, G., Eich, H. T., Klemke, C. D., Mitteldorf, C., Nicolay, J. P., Theurich, S., Wobser, M., & Stadler, R. (2025). Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 23(3), 341-354. https://doi.org/10.1111/ddg.15639
Vancouver
Assaf C, Booken N, Dippel E, Dobos G, Eich HT, Klemke CD, et al. Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025;23(3):341-354. doi:10.1111/ddg.15639
BibTeX
@article{Assaf2025,
author = {Assaf, Chalid and Booken, Nina and Dippel, Edgar and Dobos, Gabor and Eich, Hans-Theodor and Klemke, Claus-Detlev and Mitteldorf, Christina and Nicolay, Jan P and Theurich, Sebastian and Wobser, Marion and Stadler, Rudolf},
title = {Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
volume = {23},
number = {3},
pages = {341--354},
doi = {10.1111/ddg.15639}
}
EUVIMED